{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:33:35Z","timestamp":1784918015337,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"grant-in-aid for scientific research from japan ministry of education, culture, sports, science, and technology","award":["19K09003"],"award-info":[{"award-number":["19K09003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11102-021-01192-x","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T16:02:17Z","timestamp":1636819337000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay"],"prefix":"10.1007","volume":"25","author":[{"given":"Atsushi","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-653X","authenticated-orcid":false,"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"issue":"11","key":"1192_CR1","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P et al (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86(11):5256\u20135261","journal-title":"J Clin Endocrinol Metab"},{"key":"1192_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients. Eur J Endocrinol 160:747\u2013752","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1192_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11102-019-01000-7","volume":"23","author":"H Lasolle","year":"2020","unstructured":"Lasolle H, Ilie MD, Raverot G (2020) Aggressive prolactinomas: How to manage? Pituitary 23(1):70\u201377","journal-title":"Pituitary"},{"issue":"5","key":"1192_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s11102-018-0898-y","volume":"21","author":"W Liu","year":"2018","unstructured":"Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M (2018) Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: A retrospective single center study. Pituitary 21(5):454\u2013462","journal-title":"Pituitary"},{"key":"1192_CR5","doi-asserted-by":"publisher","first-page":"616339","DOI":"10.3389\/fendo.2021.616339","volume":"12","author":"H Tang","year":"2021","unstructured":"Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB (2021) Case Report: Temozolomide treatment of refractory prolactinoma resistant to dopamine agonists. Front Endocrinol (Lausanne) 12:616339","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1192_CR6","first-page":"139","volume":"16","author":"MH Almalki","year":"2017","unstructured":"Almalki MH, Aljoaib NN, Alotaibi MJ et al (2017) Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: A systematic review. Hormones (Athens) 16(2):139\u2013149","journal-title":"Hormones (Athens)"},{"key":"1192_CR7","doi-asserted-by":"publisher","first-page":"624686","DOI":"10.3389\/fendo.2021.624686","volume":"12","author":"T Nakano-Tateno","year":"2021","unstructured":"Nakano-Tateno T, Lau KJ, Wang J et al (2021) Multimodal non-surgical treatments of aggressive pituitary tumors. Front Endocrinol (Lausanne) 12:624686","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1192_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey 2016. Eur JEndocrinol 178:265\u2013276","journal-title":"Eur JEndocrinol"},{"issue":"6","key":"1192_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2018-02461","volume":"104","author":"D Zhang","year":"2019","unstructured":"Zhang D, Way JS, Zhang X et al (2019) Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104(6):1929\u20131936","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1192_CR10","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","volume":"106","author":"O Cooper","year":"2021","unstructured":"Cooper O, Bonert VS, Rudnick J et al (2021) EGFR\/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106(2):e917\u2013e925","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1192_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/jpm10030088","volume":"10","author":"C Duhamel","year":"2020","unstructured":"Duhamel C, Ilie MD, Salle H et al (2020) Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: Two case reports and a review of the literature. J Pers Med 10(3):88","journal-title":"J Pers Med"},{"issue":"41","key":"1192_CR12","doi-asserted-by":"publisher","first-page":"e12784","DOI":"10.1097\/MD.0000000000012784","volume":"97","author":"Y Lu","year":"2018","unstructured":"Lu Y, Zhao Z, Wang J et al (2018) Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis. Med (Baltim) 97(41):e12784","journal-title":"Med (Baltim)"},{"key":"1192_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12022-020-09647-w","volume":"32","author":"T Nakano-Tateno","year":"2020","unstructured":"Nakano-Tateno T, Satou M, Inoshita N et al (2020) Effects of CAPTEM (capecitabine and temozolomide) on a corticotroph carcinoma and an aggressive corticotroph tumor. Endocr Pathol 32:418\u2013426","journal-title":"Endocr Pathol"},{"issue":"4","key":"1192_CR14","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","volume":"74","author":"BE Zacharia","year":"2014","unstructured":"Zacharia BE, Gulati AP, Bruce JN et al (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): A case series. Neurosurgery 74(4):E447\u2013E455","journal-title":"Neurosurgery"},{"key":"1192_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fendo.2018.00318","volume":"9","author":"LV Syro","year":"2018","unstructured":"Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, Kovacs K (2018) Temozolomide and pituitary tumors: Current understanding, unresolved issues, and future directions. Front Endocrinol (Lausanne) 9:318","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1192_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11154-020-09551-y","volume":"21","author":"P Burman","year":"2020","unstructured":"Burman P, Lamb L, McCormack A (2020) Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives. Rev Endocr Metab Disord 21(2):263\u2013276","journal-title":"Rev Endocr Metab Disord"},{"issue":"6378","key":"1192_CR17","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359(6378):920\u2013926","journal-title":"Science"},{"issue":"6444","key":"1192_CR18","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers H (2019) Cancer modeling meets human organoid technology. Science 364(6444):952\u2013955","journal-title":"Science"},{"issue":"3","key":"1192_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3(3):198\u2013210","journal-title":"Genes Dis"},{"issue":"6","key":"1192_CR20","doi-asserted-by":"publisher","first-page":"E1761","DOI":"10.1227\/NEU.0b013e318217161a","volume":"68","author":"M Murakami","year":"2011","unstructured":"Murakami M, Mizutani A, Asano S et al (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761\u2013E1767","journal-title":"Neurosurgery"},{"issue":"1","key":"1192_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00795-013-0050-z","volume":"47","author":"A Matsuno","year":"2014","unstructured":"Matsuno A, Murakami M, Hoya K et al (2014) Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. Med Mol Morphol 47(1):1\u20137","journal-title":"Med Mol Morphol"},{"issue":"6","key":"1192_CR22","doi-asserted-by":"publisher","first-page":"143664","DOI":"10.1210\/jendso\/bvab055","volume":"5","author":"Y Tsujimoto","year":"2021","unstructured":"Tsujimoto Y, Shichi H, Fukuoka H et al (2021) Tumor shrinkage by metyrapone in cushing disease exhibiting glucocorticoid-induced positive feedback. J Endocr Soc 5(6):143664","journal-title":"J Endocr Soc"},{"issue":"1","key":"1192_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1208\/s12248-020-00533-1","volume":"23","author":"JM Janssen","year":"2021","unstructured":"Janssen JM, Jacobs BAW, Roosendaal J et al (2021) Population pharmacokinetics of intracellular 5-Fluorouridine 5\u2019-Triphosphate and its relationship with hand-and-foot syndrome in patients treated with capecitabine. AAPS J 23(1):23","journal-title":"AAPS J"},{"key":"1192_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.25259\/SNI_860_2020","volume":"12","author":"A Ishida","year":"2021","unstructured":"Ishida A, Asakuno K, Kato M et al (2021) Treatment of an anterior cerebral artery pseudoaneurysm secondary to a transsphenoidal surgery using stent-assisted coiling. Surg Neurol Int 12:20","journal-title":"Surg Neurol Int"},{"issue":"4","key":"1192_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schr\u00f8der HD, Andersen M et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689\u20131698","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1192_CR26","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A et al (2018) European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013G24","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1192_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle H, Cortet C, Castinetti F et al (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176(6):769\u2013777","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1192_CR28","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130\u20131136","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1192_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","volume":"126","author":"M Losa","year":"2016","unstructured":"Losa M, Bogazzi F, Cannavo S et al (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126(3):519\u2013525","journal-title":"J Neurooncol"},{"issue":"11","key":"1192_CR30","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T et al (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280\u2013E290","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"1192_CR31","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","volume":"15","author":"S Yip","year":"2009","unstructured":"Yip S, Miao J, Cahill DP et al (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15(14):4622\u20134629","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1192_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11102-017-0829-3","volume":"20","author":"ASG Micko","year":"2017","unstructured":"Micko ASG, W\u00f6hrer A, H\u00f6ftberger R et al (2017) MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. Pituitary 20(6):643\u2013653","journal-title":"Pituitary"},{"issue":"5\u20136","key":"1192_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.drudis.2012.10.003","volume":"18","author":"S Breslin","year":"2013","unstructured":"Breslin S, O\u2019Driscoll L (2013) Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18(5\u20136):240\u2013249","journal-title":"Drug Discov Today"},{"issue":"2","key":"1192_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11102-015-0694-x","volume":"19","author":"M Campder\u00e1","year":"2016","unstructured":"Campder\u00e1 M, Palacios N, Aller J et al (2016) Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. Pituitary 19(2):158\u2013166","journal-title":"Pituitary"},{"issue":"10","key":"1192_CR35","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V et al (2018) Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab 103(10):3925\u20133930","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1192_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke MH, Hornick JL, Frauenhoffer C et al (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338\u2013345","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1192_CR37","first-page":"1461","volume":"17","author":"J Murakami","year":"2007","unstructured":"Murakami J, Lee YJ, Kokeguchi S et al (2007) Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol Rep 17(6):1461\u20131467","journal-title":"Oncol Rep"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","volume":"80","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Vasiljevic A, Borson-Chazot F, Raverot G (2019) Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol 80:84\u201388","journal-title":"Ann Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01192-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T15:12:18Z","timestamp":1646320338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01192-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01192-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"29 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no multiplicity of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study protocols were approved by the Moriyama Memorial Hospital Institutional Review Board. Informed consent was obtained from the patients. 3D spheroid culture experiments were conducted in compliance with the protocol that was reviewed and approved by the Research Ethics Committee of Kobe University Hospital (IRB#1363).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}